Anders Månsson
Interim CEO since 2025. Employed since October 2025. Born 1967.
Background: Strong background in the life science industry, having held senior executive positions in large multinationals, such as Ferring Pharmaceuticals and LEO Pharma, as well as CEO and board level roles in several smaller biotech companies.
Education: BSc, Business & Economics, Lund University and MBA Business School Lausanne.
Other assignments: Member of Board of EQL Pharma AB (public) and Immetric AB.
Previous assignments in the past five years: Industrial Advisor in the Life Science area to large-cap Private Equity company, Ratos AB. CEO of Phase Holographic Imaging AB, Oncoinvent AS, LIDDS AB and RhoVac AB.
Holding: 0 shares
Mikael Arinder
Head of Science and Technology since 2016. Employed since 2016. Born 1964.
Background: Over 15 years’ experience in the development of inhalation products from AstraZeneca and Iconovo. Has held roles as project manager for pharmaceutical, medical device and technology projects at AstraZeneca, J&J and Atos Medical.
Education: PhD, Organic Chemistry, Lund University.
Other assignments: -
Previous assignments in the past five years:
Holding: 19,178 shares
Vesna Åkerberg
Head of Novel and Reformulation Development since 2023. Employed since 2017. Born 1974.
Background: 14 years of inhalation experience, mainly from AstraZeneca and 10 years experience from line managerial positions in several companies, mainly from product/ process/ analytical development. Worked with product development within the pharmaceutical industry, mainly within formulation development of dry powder formulations. Experience from manufacturing of clinical trial material.
Education: MSc. Biomedical Technology
Holding: 2,651 shares
Henrik Damkjær Simonsen
CFO since 2023. Born 1963.
Background: More than 30 years’ experience in life science with leading positions in banking and healthcare industry at Nordea, Skandinaviska Enskilda Banken (SEB), Nuevolution AB (publ) and SAGA Diagnostics AB.
Education: MSc in Economics, Copenhagen University.
Other assignments: -
Previous assignments in the past five years: Finance Director at SAGA Diagnostics AB and CFO at Nuevolution AB (publ).
Holding: -
Maria Ekblad
Head of Generics Development since 2023
Background: 25+ years of experience in pre-clinical and clinical pharmaceutical development, holding management positions in both line and project organizations.
Education: MSc. Chemical Engineering
Other assignments: -
Holding: 10.000 shares
Måns Österberg Widerstrand
Director Business Development and Alliances
Background: Worked in pharmaceutical industry for over 20 years. Various positions within Manufacturing, R&D, Medical Affairs, API Sales and Key Account Management
Education: MSc. MSc. Chemical Engineering, Executive Master in Medical Business Strategy
Follow us on Linkedin
